Image Place holder

Daniel Sullivan, MD


Specialty: Internal Medicine
Program: Blood and Marrow Transplant and Cellular Immunotherapy

Call 1-888-MOFFITT
(1-888-663-3488)

or call 1-888-MOFFITT
(1-888-663-3488)

Overview

Dr. Daniel Sullivan is a senior member of the Department of Blood and Marrow Transplant at Moffitt Cancer and executive president and associate center director, Clinical Investigations.  He is chief medical officer for M2Gen, a Moffitt Cancer Center biotechnology company. He is also a professor at the University of South Florida’s Departments of Oncologic Sciences, Internal Medicine and Molecular Medicine. Dr. Sullivan’s research interests include the mechanism of drug resistance to common anti-tumor agents for patient with hematologic malignancies, small cell lung cancer, malignant melanoma and rectal carcinoma. Dr. Sullivan received his bachelor’s degree and medical degree, followed by a master’s degree in biochemistry from the University of Louisville, KY.  He completed a fellowship in hematology/oncology from the University of Florida. Before coming to Moffitt in 1995, Dr. Sullivan was an associate professor at the University of Louisville in the Department of Biochemistry and Medicine. Dr. Sullivan is a member of numerous editorial boards and national councils.  He is co-chair of the National Cancer Institute (NCI) Investigational Drug Steering Committee, a member of the NCI Operational Efficiency Work Group and has served as chair of the American Cancer Society Cancer Drug Development Peer Review Committee.  In addition, he is a grant reviewer for the National Institutes of Health and a manuscript reviewer for 19 different peer-reviewed publications. Dr. Sullivan has received numerous professional awards and has been named one of America’s Best Doctors for nine years in a row.

Education & Training

Fellowship:

  • University of Florida - Hematology/Oncology

Residency:

  • University of Florida - Internal Medicine

Medical School:

  • University of Louisville - MD
Participating Trials

CLINICAL TRIAL 18346
Evaluating the Safety and Biological Activity of a Dendritic Cell Survivin Vaccine in Patients with Multiple Myeloma Undergoing Autologous Hematopoietic Cell Transplantation
Condition: Malignant Hematology
Intervention: G-CSF; Prevnar13; Survivin-Dendritic Cell Vaccine
Open

CLINICAL TRIAL 18217
Multicenter Phase II, Double-blind Placebo Controlled Trial of Maintenance Ixazomib after Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Multiple Myeloma
Condition: Malignant Hematology
Intervention: Alkeran (Melphalan); Bortezomib; FK506 (Tacrolimus); Ixazomib (Ninlaro); Melphalan; Not Applicable; PS-341 (Bortezomib); Placebo; Tacrolimus; Velcade (Bortezomib); fludarabine (Fludarabine phosphate); methotrexate
Open

CLINICAL TRIAL 17690
A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients with Hepatic Dysfunction
Condition: Multiple
Intervention: GSK1120212 (Trametinib); Trametinib
Open

CLINICAL TRIAL 18521
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE)Compound KPT-8602 in Patients with Relapsed/Refractory Cancer Indications
Condition: Multiple
Intervention: Abiraterone acetate; Dexamethasone; KPT-8602; Zytiga (Abiraterone acetate)
Open

CLINICAL TRIAL 19079
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of Oprozomib in Combination with Pomalidomide and Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma
Condition: Malignant Hematology
Intervention: CC-4047 (Pomalidomide); Dexamethasone; Oprozomib; Pomalidomide
Open

CLINICAL TRIAL 19230
Phase 2, Randomized, Open-Label Study Comparing Daratumumab, Lenalidomide, Bortezomib,and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma Eligible for High-Dose Chemotherapy and Autologous Stem Cell Transplantation
Condition: Malignant Hematology
Intervention: Bortezomib; CC-5013 (Lenalidomide); Daratumumab; Dexamethasone; Lenalidomide (Revlimid); PS-341 (Bortezomib); Velcade (Bortezomib)
Open

If you believe you are eligible for one of these trials or studies, please call
1-888-MOFFITT (1-888-663-3488).

Publications

  • Li B, Eschrich SA, Berglund A, Mitchell M, Fenstermacher D, Danaee H, Dai H, Sullivan D, Trepicchio WL, Dalton WS. Use of the Total Cancer Care System to Enrich Screening for CD30-Positive Solid Tumors for Patient Enrollment Into a Brentuximab Vedotin Clinical Trial: A Pilot Study to Evaluate Feasibility. JMIR Res Protoc. 2017 Mar;6(3):e45. Pubmedid: 28320689. Pmcid: PMC5379017.
  • Rollison DE, Komrokji R, Lee JH, Hampras S, Fulp W, Fisher K, Baz R, Nishihori T, Xu Q, Olesnyckyj M, Kenvin L, Knight R, Sullivan D, Alsina M, Dalton W, Shain KH. Subsequent primary malignancies among multiple myeloma patients treated with or without lenalidomide. Leuk Lymphoma. 2017 Mar;58(3):560-568. Pubmedid: 27424609.
  • Shay G, Tauro M, Loiodice F, Tortorella P, Sullivan DM, Hazlehurst LA, Lynch CC. Selective inhibition of matrix metalloproteinase-2 in the multiple myeloma-bone microenvironment. Oncotarget. 2017 Jun;8(26):41827-41840. Pubmedid: 28611279. Pmcid: PMC5522031.
  • Chiappori AA, Otterson GA, Dowlati A, Traynor AM, Horn L, Owonikoko TK, Ross HJ, Hann CL, Abu Hejleh T, Nieva J, Zhao X, Schell M, Sullivan DM. A Randomized Phase II Study of Linsitinib (OSI-906) Versus Topotecan in Patients With Relapsed Small-Cell Lung Cancer. Oncologist. 2016 Oct;21(10):1163-1164. Pubmedid: 27694157. Pmcid: PMC5061534.
  • Turner JG, Kashyap T, Dawson JL, Gomez J, Bauer AA, Grant S, Dai Y, Shain KH, Meads M, Landesman Y, Sullivan DM. XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma. Oncotarget. 2016 Nov;7(48):78896-78909. Pubmedid: 27806331. Pmcid: PMC5340237.
  • Pisklakova A, Grigson E, Ozerova M, Chen F, Sullivan DM, Nefedova Y. Anti-myeloma effect of pharmacological inhibition of Notch/gamma-secretase with RO4929097 is mediated by modulation of tumor microenvironment. Cancer Biol Ther. 2016 May;17(5):477-485. Pubmedid: 26934342. Pmcid: PMC4910908.
  • Baz RC, Martin TG, Lin HY, Zhao X, Shain KH, Cho HJ, Wolf JL, Mahindra A, Chari A, Sullivan DM, Nardelli LA, Lau K, Alsina M, Jagannath S. Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma. Blood. 2016 May;127(21):2561-2568. Pubmedid: 26932802.
  • Holkova B, Zingone A, Kmieciak M, Bose P, Badros AZ, Voorhees PM, Baz R, Korde N, Lin HY, Chen JQ, Herrmann MA, Xi L, Raffeld M, Zhao X, Wan W, Tombes MB, Shrader E, Weir-Wiggins C, Sankala HM, Hogan K, Doyle A, Annunziata CM, Wellons M, Roberts JD, Sullivan DM, Landgren O, Grant S. A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma. Clin Cancer Res. 2016 Mar;22(5):1067-1075. Pubmedid: 26446942. Pmcid: PMC4775365.
  • Kummar S, Wade JL, Oza AM, Sullivan D, Chen AP, Gandara DR, Ji J, Kinders RJ, Wang L, Allen D, Coyne GO, Steinberg SM, Doroshow JH. Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer. Invest New Drugs. 2016 Jun;34(3):355-363. Pubmedid: 26996385. Pmcid: PMC4860030.
  • Reed DR, Mascarenhas L, Manning K, Hale GA, Goldberg J, Gill J, Sandler E, Isakoff MS, Smith T, Caracciolo J, Lush RM, Juan TH, Lee JK, Neuger AM, Sullivan DM. Pediatric phase I trial of oral sorafenib and topotecan in refractory or recurrent pediatric solid malignancies. Cancer Med. 2016 Feb;5(2):294-303. Pubmedid: 26714427. Pmcid: PMC4735769.
  • Turner JG, Dawson JL, Grant S, Shain KH, Dalton WS, Dai Y, Meads M, Baz R, Kauffman M, Shacham S, Sullivan DM. Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors. J Hematol Oncol. 2016 Aug;9(1):73. Pubmedid: 27557643. Pmcid: PMC4997728.
  • Soliman HH, Minton SE, Han HS, Ismail-Khan R, Neuger A, Khambati F, Noyes D, Lush R, Chiappori AA, Roberts JD, Link C, Vahanian NN, Mautino M, Streicher H, Sullivan DM, Antonia SJ. A phase I study of indoximod in patients with advanced malignancies. Oncotarget. 2016 Apr;7(16):22928-22938. Pubmedid: 27008709. Pmcid: PMC5008412.
  • Denson A, Burke N, Wapinsky G, Bertels B, Juan TH, Lee J, Springett GM, Strosberg JR, Kim RD, Sullivan DM, Mahipal A. Clinical Outcomes of Patients With Gastrointestinal Malignancies Participating in Phase I Clinical Trials. Am J Clin Oncol. 2015 Oct. Pubmedid: 26523441. Pmcid: PMC4980275.
  • Seymour L, Groshen S, Rosner GL, Sullivan DM, Spriggs DR, Reeves S, Gravell A, Ivy SP, Ratain MJ. Impact of the 2010 Consensus Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee. Clin Cancer Res. 2015 Nov;21(22):5057-5063. Pubmedid: 26567365. Pmcid: PMC4646725.
  • Yu D, Kahen E, Cubitt CL, McGuire J, Kreahling J, Lee J, Altiok S, Lynch CC, Sullivan DM, Reed DR. Identification of Synergistic, Clinically Achievable, Combination Therapies for Osteosarcoma. Sci Rep. 2015 Nov;5:16991. Pubmedid: 26601688. Pmcid: PMC4658502.
  • Nishihori T, Baz R, Shain K, Kim J, Ochoa-Bayona JL, Yue B, Sullivan D, Dalton W, Alsina M. An open-label phase I/II study of cyclophosphamide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed myeloma. Eur J Haematol. 2015 Nov;95(5):426-435. Pubmedid: 25600676. Pmcid: PMC4508238.
  • Appleyard CB, Antonia SJ, Sullivan DM, Santiago-Cardona PG, Cáceres W, Velez H, Torres-Ruiz JA, Wright KL. Building a long distance training program to enhance clinical cancer research capacity in Puerto Rico. Rev Recent Clin Trials. 2015 Mar;9(4):254-262. Pubmedid: 25626061. Pmcid: PMC4378863.
  • Kazim S, Malafa MP, Coppola D, Husain K, Zibadi S, Kashyap T, Crochiere M, Landesman Y, Rashal T, Sullivan DM, Mahipal A. Selective Nuclear Export Inhibitor KPT-330 Enhances the Antitumor Activity of Gemcitabine in Human Pancreatic Cancer. Mol Cancer Ther. 2015 Jul;14(7):1570-1581. Pubmedid: 25934708. Pmcid: PMC4577050.
  • Grigson ER, Ozerova M, Pisklakova A, Liu H, Sullivan DM, Nefedova Y. Canonical Wnt pathway inhibitor ICG-001 induces cytotoxicity of multiple myeloma cells in Wnt-independent manner. PLoS One. 2015 Jan;10(1):e0117693. Pubmedid: 25635944. Pmcid: PMC4311909.
  • Kummar S, Fleming GF, Oza AM, Sullivan DM, Gandara DR, Naughton M, Villalona-Calero MA, Morgan R, Szabo PM, Youn A, Chen A, Ji JJ, Allen D, Lih CJ, Mehaffey MG, Walsh WD, McGregor PM, Steinberg SM, Williams PM, Kinders R, Conley BA, Simon RM, Doroshow JH. Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer. Clin Cancer Res. 2015 Apr;21(7):1574-1582. Pubmedid: 25589624. Pmcid: PMC4383665.
  • Mahipal A, Denson AC, Djulbegovic B, Lush R, Kumar A, Juan TH, Schell MJ, Sullivan DM. Effect of Age on Clinical Outcomes in Phase 1 Trial Participants. Cancer Control. 2015 Apr;22(2):235-241. Pubmedid: 26068771.
  • Soliman HH, Jackson E, Neuger T, Dees EC, Harvey RD, Han H, Ismail-Khan R, Minton S, Vahanian NN, Link C, Sullivan DM, Antonia S. A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors. Oncotarget. 2014 Sep;5(18):8136-8146. Pubmedid: 25327557. Pmcid: PMC4226672.
  • Yap TA, Yan L, Patnaik A, Tunariu N, Biondo A, Fearen I, Papadopoulos K, Olmos D, Baird RD, Delgado LM, Tetteh E, Beckman RA, Lupinacci L, Riisnaes R, Decordova S, Heaton SP, Swales K, deSouza NM, Leach MO, Garrett MD, Sullivan DM, de Bono JS, Tolcher A. Interrogating two schedules of the AKT inhibitor MK-2206 in patients with advanced solid tumors incorporating novel pharmacodynamic and functional imaging biomarkers. Clin Cancer Res. 2014 Nov;20(22):5672-5685. Pubmedid: 25239610. Pmcid: PMC4233149.
  • Brana I, Berger R, Golan T, Haluska P, Edenfield J, Fiorica J, Stephenson J, Martin LP, Westin S, Hanjani P, Jones MB, Almhanna K, Wenham RM, Sullivan DM, Dalton WS, Gunchenko A, Cheng JD, Siu LL, Gray JE. A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours. Brit J Cancer. 2014 Nov;111(10):1932-1944. Pubmedid: 25290091. Pmcid: PMC4229637.
  • Holkova B, Kmieciak M, Perkins EB, Bose P, Baz R, Roodman GD, Stuart RK, Ramakrishnan V, Wan W, Peer CJ, Dawson JL, Kang L, Honeycutt C, Tombes MB, Shrader E, Weir-Wiggins C, Wellons M, Sankala HM, Hogan K, Colevas AD, Doyle A, Figg WD, Coppola D, Roberts JD, Sullivan DM, Grant S. Phase I trial of bortezomib (PS-341; NSC 681239) and "nonhybrid" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms. Clin Cancer Res. 2014 Nov;20(22):5652-5662. Pubmedid: 25248382. Pmcid: PMC4233160.
  • Molife LR, Yan L, Vitfell-Rasmussen J, Zernhelt AM, Sullivan DM, Cassier PA, Chen E, Biondo A, Tetteh E, Siu LL, Patnaik A, Papadopoulos KP, de Bono JS, Tolcher AW, Minton S. Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors. J Hematol Oncol. 2014 Jan;7:1. Pubmedid: 24387695. Pmcid: PMC3884022.
  • Baz RC, Shain KH, Hussein MA, Lee JH, Sullivan DM, Finleyoliver E, Nardelli LA, Nodzon LA, Zhao X, Ochoa-Bayona JL, Nishihori T, Dalton WS, Alsina M. Phase II study of pegylated liposomal doxorubicin, low-dose dexamethasone, and lenalidomide in patients with newly diagnosed multiple myeloma. Am J Hematol. 2014 Jan;89(1):62-67. Pubmedid: 24030918. Pmcid: PMC4522918.
  • Bode B, Stenlöf K, Harris S, Sullivan D, Fung A, Usiskin K, Meininger G. Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes. Diabetes Obes Metab. 2014 Dec. Pubmedid: 25495720.
  • Turner JG, Dawson J, Cubitt CL, Baz R, Sullivan DM. Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents. Semin Cancer Biol. 2014 Aug;27:62-73. Pubmedid: 24631834. Pmcid: PMC4108511.
  • Turner JG, Dawson J, Emmons MF, Cubitt CL, Kauffman M, Shacham S, Hazlehurst LA, Sullivan DM. CRM1 Inhibition Sensitizes Drug Resistant Human Myeloma Cells to Topoisomerase II and Proteasome Inhibitors both In Vitro and Ex Vivo. J Cancer. 2013 Sep;4(8):614-625. Pubmedid: 24155773. Pmcid: PMC3805989.
  • Nishihori T, Ochoa-Bayona JL, Kim J, Pidala J, Shain K, Baz R, Sullivan D, Jim HS, Anasetti C, Alsina M. Allogeneic hematopoietic cell transplantation for consolidation of VGPR or CR for newly diagnosed multiple myeloma. Bone Marrow Transplant. 2013 Sep;48(9):1179-1184. Pubmedid: 23542223. Pmcid: PMC4500071.
  • Baz R, Miladinovic B, Patel A, Ho VQ, Shain KH, Alsina M, Nishihori T, Ochoa-Bayona JL, Sullivan DM, Dalton WS, Djulbegovic B. Sequence of novel agents in multiple myeloma: an instrumental variable analysis. Leuk Res. 2013 Sep;37(9):1077-1082. Pubmedid: 23809054.
  • Almhanna K, Cubitt CL, Zhang S, Kazim S, Husain K, Sullivan D, Sebti S, Malafa M. MK-2206, an Akt inhibitor, enhances carboplatinum/paclitaxel efficacy in gastric cancer cell lines. Cancer Biol Ther. 2013 Oct;14(10):932-936. Pubmedid: 23917345. Pmcid: PMC3926890.
  • Cubitt CL, Menth J, Dawson J, Martinez GV, Foroutan P, Morse DL, Bui MM, Letson GD, Sullivan DM, Reed DR. Rapid screening of novel agents for combination therapy in sarcomas. Sarcoma. 2013 Nov;2013:365723. Pubmedid: 24282374. Pmcid: PMC3824404.
  • Hudis C, Swanton C, Janjigian YY, Lee R, Sutherland S, Lehman R, Chandarlapaty S, Hamilton N, Gajria D, Knowles J, Shah J, Shannon K, Tetteh E, Sullivan DM, Moreno C, Yan L, Han HS. A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors. Breast Cancer Res. 2013 Nov;15(6):R110. Pubmedid: 24252402. Pmcid: PMC3979046.
  • Richardson PG, Siegel D, Baz R, Kelley SL, Munshi NC, Laubach J, Sullivan D, Alsina M, Schlossman R, Ghobrial IM, Doss D, Loughney N, McBride L, Bilotti E, Anand P, Nardelli L, Wear S, Larkins G, Chen M, Zaki MH, Jacques C, Anderson KC. Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. Blood. 2013 Mar;121(11):1961-1967. Pubmedid: 23243282. Pmcid: PMC4123324.
  • Abrams JS, Mooney MM, Zwiebel JA, Korn EL, Friedman SH, Finnigan SR, Schettino PR, Denicoff AM, Kruhm MG, Montello M, Misra RR, Ansher SS, Dipiazza KJ, Souhan EM, Wickerham DL, Giantonio BJ, O'Donnell RT, Sullivan DM, Soto NI, Fleming GF, Prindiville SA, Petryshyn RA, Hautala JA, Grad O, Zuckerman BL, Meyer RM, Yao JC, Baker LA, Buckner JC, Hortobagyi GN, Doroshow JH. Implementation of timeline reforms speeds initiation of National Cancer Institute-sponsored trials. J Natl Cancer Inst. 2013 Jul;105(13):954-959. Pubmedid: 23776198. Pmcid: PMC3699438.
  • Lush RM, Patnaik A, Sullivan D, Papadopoulos KP, Trucksis M, McCrea J, Cerchio K, Li X, Stroh M, Selverian D, Orford K, Ebbinghaus S, Agrawal N, Iwamoto M, Wagner JA, Tolcher A. A single supratherapeutic dose of ridaforolimus does not prolong the QTc interval in patients with advanced cancer. Cancer Chemother Pharmacol. 2012 Oct;70(4):567-574. Pubmedid: 22878520. Pmcid: PMC3456920.
  • Ramakrishnan R, Huang C, Cho HI, Lloyd M, Johnson J, Ren X, Altiok S, Sullivan D, Weber J, Celis E, Gabrilovich DI. Autophagy induced by conventional chemotherapy mediates tumor cell sensitivity to immunotherapy. Cancer Res. 2012 Nov;72(21):5483-5493. Pubmedid: 22942258. Pmcid: PMC4577568.
  • Strosberg JR, Yeatman T, Weber J, Coppola D, Schell MJ, Han G, Almhanna K, Kim R, Valone T, Jump H, Sullivan D. A phase II study of RO4929097 in metastatic colorectal cancer. Eur J Cancer. 2012 May;48(7):997-1003. Pubmedid: 22445247. Pmcid: PMC4522922.
  • Nishihori T, Alekshun TJ, Shain K, Sullivan DM, Baz R, Perez L, Pidala J, Kharfan-Dabaja MA, Ochoa-Bayona JL, Fernandez HF, Yarde DN, Oliveira V, Fulp W, Han G, Kim J, Chen DT, Raychaudhuri J, Dalton W, Anasetti C, Alsina M. Bortezomib salvage followed by a Phase I/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma. Brit J Haematol. 2012 Jun;157(5):553-563. Pubmedid: 22449149. Pmcid: PMC4030553.
  • Jacobsen PB, Wells KJ, Meade CD, Quinn GP, Lee JH, Fulp WJ, Gray JE, Baz RC, Springett GM, Levine RM, Markham MJ, Schreiber FJ, Cartwright TH, Burke JM, Siegel RD, Malafa MP, Sullivan D. Effects of a brief multimedia psychoeducational intervention on the attitudes and interest of patients with cancer regarding clinical trial participation: a multicenter randomized controlled trial. J Clin Oncol. 2012 Jul;30(20):2516-2521. Pubmedid: 22614993. Pmcid: PMC4577714.
  • Perkins JB, Kim J, Anasetti C, Fernandez HF, Perez LE, Ayala E, Kharfan-Dabaja MA, Tomblyn MR, Sullivan DM, Pidala JA, Field TL. Maximally tolerated busulfan systemic exposure in combination with fludarabine as conditioning before allogeneic hematopoietic cell transplantation. Biol Blood Marrow Tr. 2012 Jul;18(7):1099-1107. Pubmedid: 22198540.
  • Turner JG, Dawson J, Sullivan DM. Nuclear export of proteins and drug resistance in cancer. Biochem Pharmacol. 2012 Apr;83(8):1021-1032. Pubmedid: 22209898. Pmcid: PMC4521586.
  • Holkova B, Perkins EB, Ramakrishnan V, Tombes MB, Shrader E, Talreja N, Wellons MD, Hogan KT, Roodman GD, Coppola D, Kang L, Dawson J, Stuart RK, Peer C, Figg WD, Kolla S, Doyle A, Wright J, Sullivan DM, Roberts JD, Grant S. Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasms. Clin Cancer Res. 2011 May;17(10):3388-3397. Pubmedid: 21447728. Pmcid: PMC3096752.
  • Lancet JE, Duong VH, Winton EF, Stuart RK, Burton M, Zhang S, Cubitt C, Blaskovich MA, Wright JJ, Sebti S, Sullivan DM. A phase I clinical-pharmacodynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced acute leukemias. Clin Cancer Res. 2011 Mar;17(5):1140-1146. Pubmedid: 21233404. Pmcid: PMC3049960.
  • O'Neil BH, Goff LW, Kauh JS, Strosberg JR, Bekaii-Saab TS, Lee RM, Kazi A, Moore DT, Learoyd M, Lush RM, Sebti SM, Sullivan DM. Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2011 Jun;29(17):2350-2356. Pubmedid: 21519015. Pmcid: PMC3107750.
  • Hartley-Brown MA, Sullivan DM, Baz R. State-of-the-Art Management of Complications of Myeloma and Its Treatment. Adv Hematol. 2011 Jul;2010:343089. Pubmedid: 20671999. Pmcid: PMC2905716.
  • Reece DE, Sullivan D, Lonial S, Mohrbacher AF, Chatta G, Shustik C, Burris H, Venkatakrishnan K, Neuwirth R, Riordan WJ, Karol M, von Moltke LL, Acharya M, Zannikos P, Keith Stewart A. Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma. Cancer Chemother Pharmacol. 2011 Jan;67(1):57-67. Pubmedid: 20306195.
  • Lebovic D, Zhang L, Alsina M, Nishihori T, Shain KH, Sullivan D, Ochoa-Bayona JL, Kharfan-Dabaja MA, Baz R. Clinical outcomes of patients with plasma cell leukemia in the era of novel therapies and hematopoietic stem cell transplantation strategies: a single-institution experience. Clin Lymphoma Myeloma Leuk. 2011 Dec;11(6):507-511. Pubmedid: 21813352.
  • Garrett CR, Coppola D, Wenham RM, Cubitt CL, Neuger AM, Frost TJ, Lush RM, Sullivan DM, Cheng JQ, Sebti SM. Phase I pharmacokinetic and pharmacodynamic study of triciribine phosphate monohydrate, a small-molecule inhibitor of AKT phosphorylation, in adult subjects with solid tumors containing activated AKT. Invest New Drugs. 2011 Dec;29(6):1381-1389. Pubmedid: 20644979. Pmcid: PMC4612514.
  • Chen F, Pisklakova A, Li M, Baz R, Sullivan DM, Nefedova Y. Gamma-secretase inhibitor enhances the cytotoxic effect of bortezomib in multiple myeloma. Cell Oncol (Dordr). 2011 Dec;34(6):545-551. Pubmedid: 21965140. Pmcid: PMC3417352.
  • Perkins JB, Goldstein SC, Dawson JL, Kim J, Field TL, Partyka JS, Fields KK, Maddox BL, Simonelli CE, Neuger AM, Lush RM, Sullivan DM. Phase I Study of Topotecan, Ifosfamide, and Etoposide (TIME) with autologous stem cell transplant in refractory cancer: pharmacokinetic and pharmacodynamic correlates. Clin Cancer Res. 2011 Dec;17(24):7743-7753. Pubmedid: 22028494. Pmcid: PMC4521635.
  • Yap TA, Yan L, Patnaik A, Fearen I, Olmos D, Papadopoulos K, Baird RD, Delgado L, Taylor A, Lupinacci L, Riisnaes R, Pope LL, Heaton SP, Thomas G, Garrett MD, Sullivan DM, de Bono JS, Tolcher AW. First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors. J Clin Oncol. 2011 Dec;29(35):4688-4695. Pubmedid: 22025163.
  • Moffitt K, Brogan F, Brown C, Kasper M, Rosenblatt J, Smallridge R, Sullivan D, Kromrey J. Statewide cancer clinical trial navigation service. J Oncol Pract. 2010 May;6(3):127-132. Pubmedid: 20808555. Pmcid: PMC2868637.
  • Perkins J, Field T, Kim J, Kharfan-Dabaja MA, Fernandez H, Ayala E, Perez L, Xu M, Alsina M, Ochoa L, Sullivan D, Janssen W, Anasetti C. A randomized phase II trial comparing tacrolimus and mycophenolate mofetil to tacrolimus and methotrexate for acute graft-versus-host disease prophylaxis. Biol Blood Marrow Tr. 2010 Jul;16(7):937-947. Pubmedid: 20102746.
  • Field T, Perkins J, Huang Y, Kharfan-Dabaja MA, Alsina M, Ayala E, Fernandez HF, Janssen W, Lancet J, Perez L, Sullivan D, List A, Anasetti C. 5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2010 Feb;45(2):255-260. Pubmedid: 19543327.
  • Li M, Chen F, Clifton N, Sullivan DM, Dalton WS, Gabrilovich DI, Nefedova Y. Combined inhibition of Notch signaling and Bcl-2/Bcl-xL results in synergistic antimyeloma effect. Mol Cancer Ther. 2010 Dec;9(12):3200-3209. Pubmedid: 21159606. Pmcid: PMC3058809.
  • Dalton WS, Sullivan DM, Yeatman TJ, Fenstermacher DA. The 2010 Health Care Reform Act: a potential opportunity to advance cancer research by taking cancer personally. Clin Cancer Res. 2010 Dec;16(24):5987-5996. Pubmedid: 21169252.
  • Turner JG, Marchion DC, Dawson JL, Emmons MF, Hazlehurst LA, Washausen P, Sullivan DM. Human multiple myeloma cells are sensitized to topoisomerase II inhibitors by CRM1 inhibition. Cancer Res. 2009 Sep;69(17):6899-6905. Pubmedid: 19690141. Pmcid: PMC2744372.
  • Homsi J, Cubitt CL, Zhang S, Munster PN, Yu H, Sullivan DM, Jove R, Messina JL, Daud AI. Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma. Melanoma Res. 2009 Jun;19(3):167-175. Pubmedid: 19434004.
  • Daud AI, Dawson J, Deconti RC, Bicaku E, Marchion D, Bastien S, Hausheer FA, Lush R, Neuger A, Sullivan DM, Munster PN. Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial. Clin Cancer Res. 2009 Apr;15(7):2479-2487. Pubmedid: 19318485.
  • Munster P, Marchion D, Bicaku E, Lacevic M, Kim J, Centeno B, Daud A, Neuger A, Minton S, Sullivan D. Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC. Clin Cancer Res. 2009 Apr;15(7):2488-2496. Pubmedid: 19318486.
  • Yeatman TJ, Mule J, Dalton WS, Sullivan D. On the eve of personalized medicine in oncology. Cancer Res. 2008 Sep;68(18):7250-7252. Pubmedid: 18794109. Pmcid: PMC2650840.
  • Moulder S, Valkov N, Neuger A, Choi J, Lee JH, Minton S, Munster P, Gump J, Lacevic M, Lush R, Sullivan D. Phase 2 study of gemcitabine and irinotecan in metastatic breast cancer with correlatives to determine topoisomerase I localization as a predictor of response. Cancer. 2008 Nov;113(10):2646-2654. Pubmedid: 18823053.
  • Chiappori AA, Haura E, Rodriguez FA, Boulware D, Kapoor R, Neuger AM, Lush R, Padilla B, Burton M, Williams C, Simon G, Antonia S, Sullivan DM, Bepler G. Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer. Clin Cancer Res. 2008 Mar;14(5):1464-1469. Pubmedid: 18316570.
  • Nefedova Y, Sullivan D, Bolick S, Dalton W, Gabrilovich D. Inhibition of Notch signaling induces apoptosis of myeloma cells and enhances sensitivity to chemotherapy. Blood. 2008 Feb;111(4):2220-2229. Pubmedid: 18039953.
  • Daud AI, DeConti RC, Andrews S, Urbas P, Riker AI, Sondak VK, Munster PN, Sullivan DM, Ugen KE, Messina JL, Heller R. Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol. 2008 Dec;26(36):5896-5903. Pubmedid: 19029422. Pmcid: PMC2645111.
  • Cangiano J, Centeno BA, Garrett CR, Caceres W, de Jesus A, Lee JH, Pavia O, Jove R, Baez L, Sullivan DM, Muro-Cacho CA, Munoz-Antonia T. Signal transduction proteins in tumors from Puerto Rican and Caucasian gastric adenocarcinoma patients: expression differences with potential for specific targeted therapies. Digest Dis Sci. 2008 Aug;53(8):2090-2100. Pubmedid: 18224443. Pmcid: PMC4467019.
  • Turner J, Sullivan D. CRM1-mediated nuclear export of proteins and drug resistance in cancer. Curr Med Chem. 2008;15(26):2648-2655. Pubmedid: 18991627.
  • Homsi J, Simon G, Garrett C, Springett G, DeConti R, Chiappori A, Munster PN, Burton M, Stromatt S, Allievi C, Angiuli P, Eisenfeld A, Sullivan D, Daud A. Phase I trial of poly-L-glutamate camptothecin (CT-2106) administered weekly in patients with advanced solid malignancies. Clin Cancer Res. 2007 Oct;13(19):5855-5861. Pubmedid: 17908979.
  • Münster P, Marchion D, Bicaku E, Schmitt M, Lee JH, DeConti R, Simon G, Fishman M, Minton S, Garrett C, Chiappori A, Lush R, Sullivan D, Daud A. Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study. J Clin Oncol. 2007 May;25(15):1979-1985. Pubmedid: 17513804.
  • Kelloff GJ, Sullivan DM, Wilson W, Cheson B, Juweid M, Mills GQ, Zelenetz AD, Horning SJ, Weber W, Sargent DJ, Dodd L, Korn E, Armitage J, Schilsky R, Christian M, O'connor OA, Wang SJ, Farrell AT, Pazdur R, Graham M, Wahl RL, Larson SM, Kostakoglu L, Daube-Witherspoon M, Gastonis C, Siegel BA, Shankar LK, Lee DB, Higley HR, Sigman CC, Carucci D, Timko D, deGennaro LJ, Sigal E, Barker A, Woodcock J. FDG-PET lymphoma demonstration project invitational workshop. Acad Radiol. 2007 Mar;14(3):330-339. Pubmedid: 17307666.
  • Fracasso PM, Burris H, Arquette MA, Govindan R, Gao F, Wright LP, Goodner SA, Greco FA, Jones SF, Willcut N, Chodkiewicz C, Pathak A, Springett GM, Simon GR, Sullivan DM, Marcelpoil R, Mayfield SD, Mauro D, Garrett CR. A phase 1 escalating single-dose and weekly fixed-dose study of cetuximab: pharmacokinetic and pharmacodynamic rationale for dosing. Clin Cancer Res. 2007 Feb;13(3):986-993. Pubmedid: 17289894.
  • de Lima Lopes G, Chiappori A, Simon G, Haura E, Sullivan D, Antonia S, Langevin M, Lush R, Rocha-Lima CM. Phase I study of carboplatin in combination with gemcitabine and irinotecan in patients with solid tumors: preliminary evidence of activity in small cell and neuroendocrine carcinomas. Cancer. 2007 Apr;109(7):1413-1419. Pubmedid: 17326096.
  • Chiappori AA, Eckhardt SG, Bukowski R, Sullivan DM, Ikeda M, Yano Y, Yamada-Sawada T, Kambayashi Y, Tanaka K, Javle MM, Mekhail T, O'bryant CL, Creaven PJ. A phase I pharmacokinetic and pharmacodynamic study of s-3304, a novel matrix metalloproteinase inhibitor, in patients with advanced and refractory solid tumors. Clin Cancer Res. 2007 Apr;13(7):2091-2099. Pubmedid: 17404091.
  • Nakanishi T, Bailey-Dell KJ, Hassel BA, Shiozawa K, Sullivan DM, Turner J, Ross DD. Novel 5' untranslated region variants of BCRP mRNA are differentially expressed in drug-selected cancer cells and in normal human tissues: implications for drug resistance, tissue-specific expression, and alternative promoter usage. Cancer Res. 2006 May;66(10):5007-5011. Pubmedid: 16707421.
  • Sharp JS, Sullivan DM, Cavanagh J, Tomer KB. Measurement of multisite oxidation kinetics reveals an active site conformational change in Spo0F as a result of protein oxidation. Biochemistry-Us. 2006 May;45(20):6260-6266. Pubmedid: 16700537.
  • Shankar LK, Hoffman JM, Bacharach S, Graham MM, Karp J, Lammertsma AA, Larson S, Mankoff DA, Siegel BA, Van den Abbeele A, Yap J, Sullivan D. Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med. 2006 Jun;47(6):1059-1066. Pubmedid: 16741317.
  • Emmons M, Boulware D, Sullivan DM, Hazlehurst LA. Topoisomerase II beta levels are a determinant of melphalan-induced DNA crosslinks and sensitivity to cell death. Biochem Pharmacol. 2006 Jun;72(1):11-18. Pubmedid: 16678798.
  • Fishman M, Garrett C, Simon G, Chiappori A, Lush R, Dinwoodie W, Mahany J, Dellaportas A, Cantor A, Gollerki A, Cohen M, Sullivan D. Phase I study of the taxane BMS-188797 in combination with carboplatin administered every 3 weeks in patients with solid malignancies. Clin Cancer Res. 2006 Jan;12(2):523-528. Pubmedid: 16428495.
  • Gritsko T, Williams A, Turkson J, Kaneko S, Bowman T, Huang M, Nam S, Eweis I, Diaz N, Sullivan D, Yoder S, Enkemann S, Eschrich S, Lee JH, Beam CA, Cheng J, Minton S, Muro-Cacho CA, Jove R. Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin Cancer Res. 2006 Jan;12(1):11-19. Pubmedid: 16397018.
  • Diaz N, Minton S, Cox C, Bowman T, Gritsko T, Garcia R, Eweis I, Wloch M, Livingston S, Seijo E, Cantor A, Lee JH, Beam CA, Sullivan D, Jove R, Muro-Cacho CA. Activation of stat3 in primary tumors from high-risk breast cancer patients is associated with elevated levels of activated SRC and survivin expression. Clin Cancer Res. 2006 Jan;12(1):20-28. Pubmedid: 16397019.
  • Hazlehurst L, Argilagos R, Emmons M, Boulware D, Beam C, Sullivan D, Dalton W. Cell adhesion to fibronectin (CAM-DR) influences acquired mitoxantrone resistance in U937 cells. Cancer Res. 2006 Feb;66(4):2338-2345. Pubmedid: 16489039.
  • Allina J, Hu B, Sullivan DM, Fiel MI, Thung SN, Bronk SF, Huebert RC, van de Water J, LaRusso NF, Gershwin ME, Gores GJ, Odin JA. T cell targeting and phagocytosis of apoptotic biliary epithelial cells in primary biliary cirrhosis. J Autoimmun. 2006 Dec;27(4):232-241. Pubmedid: 17222534.
  • Turner JG, Gump JL, Zhang C, Cook JM, Marchion D, Hazlehurst L, Munster P, Schell MJ, Dalton WS, Sullivan DM. ABCG2 expression, function, and promoter methylation in human multiple myeloma. Blood. 2006 Dec;108(12):3881-3889. Pubmedid: 16917002. Pmcid: PMC1895461.
  • Simon GR, Garrett CR, Olson SC, Langevin M, Eiseman IA, Mahany JJ, Williams CC, Lush R, Daud A, Munster P, Chiappori A, Fishman M, Bepler G, Lenehan PF, Sullivan DM. Increased bioavailability of intravenous versus oral CI-1033, a pan erbB tyrosine kinase inhibitor: results of a phase I pharmacokinetic study. Clin Cancer Res. 2006 Aug;12(15):4645-4651. Pubmedid: 16899614.
  • Simon G, Lush R, Gump J, Tetteh L, Williams C, Cantor A, Antonia S, Garrett C, Rocha-Lima C, Fishman M, Sullivan D, Munster P. Sequential oral 9-nitrocamptothecin and etoposide: a pharmacodynamic- and pharmacokinetic-based phase I trial. Mol Cancer Ther. 2006 Aug;5(8):2130-2137. Pubmedid: 16928835.
  • Marchion D, Bicaku E, Daud A, Sullivan D, Munster P. Valproic acid alters chromatin structure by regulation of chromatin modulation proteins. Cancer Res. 2005 May;65(9):3815-3822. Pubmedid: 15867379.
  • Garrett CR, Fishman MN, Rago RR, Williams CC, Dellaportas AM, Mahany JJ, Lush RM, Dalton WS, Gollerkeri A, Cohen MB, Sullivan DM. Phase I study of a novel taxane BMS-188797 in adult patients with solid malignancies. Clin Cancer Res. 2005 May;11(9):3335-3341. Pubmedid: 15867232.
  • Marchion DC, Bicaku E, Turner JG, Daud AI, Sullivan DM, Munster PN. Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta. Clin Cancer Res. 2005 Dec;11(23):8467-8475. Pubmedid: 16322310.
  • Marchion DC, Bicaku E, Daud AI, Sullivan DM, Munster PN. In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates. Mol Cancer Ther. 2005 Dec;4(12):1993-2000. Pubmedid: 16373714.
  • Lush RM, McCune J, Tetteh L, Thompson JA, Mahany JH, Garland L, Suttle AB, Sullivan DM. The absolute bioavailability of oral vinorelbine in patients with solid tumors. Cancer Chemother Pharmacol. 2005 Dec;56(6):578-584. Pubmedid: 16001165.
  • Gillies RJ, Hoffman JM, Lam KS, Menkens AE, Piwnica-Worms DR, Sullivan DC, Weissleder R. Meeting report: high-throughput technologies for in vivo imaging agents. Mol Imaging. 2005 Apr;4(2):98-103. Pubmedid: 16105507.
  • Daud A, Valkov N, Centeno B, Derderian J, Sullivan P, Munster P, Urbas P, Deconti R, Berghorn E, Liu Z, Hausheer F, Sullivan D. Phase II trial of karenitecin in patients with malignant melanoma: clinical and translational study. Clin Cancer Res. 2005 Apr;11(8):3009-3016. Pubmedid: 15837755.
  • Sood A, Lush R, Geisler J, Shahin M, Sanders L, Sullivan D, Buller R, Sorosky J. Sequential intraperitoneal topotecan and oral etoposide chemotherapy in recurrent platinum-resistant ovarian carcinoma: results of a phase II trial. Clin Cancer Res. 2004 Sep;10(18 Pt 1):6080-6085. Pubmedid: 15447993.
  • Yen Y, Margolin K, Doroshow J, Fishman M, Johnson B, Clairmont C, Sullivan D, Sznol M. A phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancer. Cancer Chemother Pharmacol. 2004 Oct;54(4):331-342. Pubmedid: 15148626.
  • Marchion DC, Bicaku E, Daud AI, Richon V, Sullivan DM, Munster PN. Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid. J Cell Biochem. 2004 May;92(2):223-237. Pubmedid: 15108350.
  • Alsina M, Fonseca R, Wilson EF, Belle AN, Gerbino E, Price-Troska T, Overton RM, Ahmann G, Bruzek LM, Adjei AA, Kaufmann SH, Wright JJ, Sullivan D, Djulbegovic B, Cantor AB, Greipp PR, Dalton WS, Sebti SM. Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. Blood. 2004 May;103(9):3271-3277. Pubmedid: 14726402.
  • Engel R, Valkov N, Gump J, Hazlehurst L, Dalton W, Sullivan D. The cytoplasmic trafficking of DNA topoisomerase IIalpha correlates with etoposide resistance in human myeloma cells. Exp Cell Res. 2004 May;295(2):421-431. Pubmedid: 15093741.
  • Turner JG, Engel R, Derderian JA, Jove R, Sullivan DM. Human topoisomerase IIalpha nuclear export is mediated by two CRM-1-dependent nuclear export signals. J Cell Sci. 2004 Jun;117(Pt 14):3061-3071. Pubmedid: 15173319.
  • Moulder S, Mahany J, Lush R, Rocha-Lima C, Langevin M, Ferrante K, Bartkowski L, Kajiji S, Noe D, Paillet S, Sullivan D. A phase I open label study of the farnesyltransferase inhibitor CP-609,754 in patients with advanced malignant tumors. Clin Cancer Res. 2004;10(21):7127-7135. Pubmedid: 15534083.
  • Valkov NI, Sullivan DM. Tumor p53 status and response to topoisomerase II inhibitors. Drug Resist Updat. 2003 Feb;6(1):27-39. Pubmedid: 12654285.
  • Hazelhurst LA, Valkov N, Wisner L, Storey JA, Boulware D, Sullivan DM, Dalton WS. Reduction in drug-induced DNA double-strand breaks associated with beta1 integrin-mediated adhesion correlates with drug resistance in U937 cells. Blood. 2001 Sep;98(6):1897-1903. Pubmedid: 11535527.
  • Fishman M, Sullivan D. Application of resistance reversal agents in hematologic malignancies; malignancy; current clinical practice. Hematology. 2001 Jun;5(5):343-358. Pubmedid: 11399634.
  • Haldane A, Sullivan D. DNA topoisomerase II-catalyzed DNA decatenation. Methods Mol Biol. 2001;95:13-23. Pubmedid: 11089215.
  • Tsai S, Valkov N, Yang W, Gump J, Sullivan D, Seto E. Histone deacetylase interacts directly with DNA topoisomerase II. Nat Genet. 2000 Nov;26(3):349-353. Pubmedid: 11062478.
  • Valkov N, Kirsch I, Gump J, Engel R, Sullivan D. Cell density-dependent VP-16 sensitivity of leukaemic cells is accompanied by the translocation of topoisomerase IIalpha from the nucleus to the cytoplasm. Br J Haematol. 2000 Feb;108(2):331-345. Pubmedid: 10691864.
  • Fishman MN, Sullivan DM. Current Clinical Practice: Application of Resistance Reversal Agents in Hematologic Malignancies. Hematology. 2000;5(5):343-358. Pubmedid: 27420926.
  • Turnbull R, Meczes E, Rogers M, Lock R, Sullivan D, Finlay G, Baguley B, Austin C. Carbamate analogues of amsacrine active against non-cycling cells: relative activity against topoisomerases IIalpha and beta. Cancer Chemother Pharmacol. 1999 Sep;44(4):275-282. Pubmedid: 10447574.
  • Hochhauser D, Valkov N, Gump J, Wei I, Fan J, O'hare C, Hartley J, Bertino J, Banerjee D, Sullivan D. Effects of wild-type p53 expression on the quality and activity of topoisomerase IIalpha and beta in various human cancer cell lines. J Cell Biochem. 1999 Nov;75(2):245-257. Pubmedid: 10502297.
  • Weitzner M, Lehninger F, Sullivan D, Fields K. Borderline personality disorder and bone marrow transplantation: ethical considerations and review. Psychol Oncol. 1999 Jan;8(1):46-54. Pubmedid: 10202782.
  • Dong Q, Johnson S, Colvin O, Bullock N, Kilborn C, Runyon G, Sullivan D, Eaton J, Bigner J, Modrich P. Multiple DNA repair mechanisms and alkylator resistance in the human medulloblastoma cell line D-283 Med (4-HCR). Cancer Chemother Pharmacol. 1999 Feb;43(1):73-79. Pubmedid: 9923544.
  • Sullivan D, Partyka J, Fields K, Goldstein S, Field T, Djulbegovic B, Perkins J, McIssac C, Lush, III R, Dalton W. A Phase I study of intensive-dose melphalan, topotecan and VP-16 phosphate (MTV) followed by autologous stem cell rescue in patients with multiple myeloma. Clin Cancer Res. 1999;5:3734s-3734s.
  • Turner JG, Tan J, Crucian BE, Sullivan DM, Ballester OF, Dalton WS, Yang NS, Burkholder JK, Yu H. Broadened clinical utility of gene gun-mediated, granulocyte-macrophage colony-stimulating factor cDNA-based tumor cell vaccines as demonstrated with a mouse myeloma model. Hum Gene Ther. 1998 May;9(8):1121-1130. Pubmedid: 9625251.
  • Fields K, Elfenbein G, Perkins J, Ballester O, Goldstein S, Heimenz J, Saez R, Sullivan D, Partyka J, Kronish L. Defining the role of novel high-dose chemotherapy regimens for the treatment of high-risk breast cancer. Semin Oncol. 1998 Apr;25(2 Suppl 4):1-6. Pubmedid: 9578055.
  • Djulbegovic B, Hozo I, Fields K, Sullivan D. High-dose chemotherapy in the adjuvant treatment of breast cancer: benefit risk analysis. Cancer Control. 1998;5:394-405. Pubmedid: 10761089.
  • Ballester OF, Tummala R, Janssen WE, Fields KK, Hiemenz JW, Goldstein SC, Perkins JB, Sullivan DM, Rosen R, Sackstein R, Zorsky P, Saez R, Elfenbein GJ. High-dose chemotherapy and autologous peripheral blood stem cell transplantation in patients with multiple myeloma and renal insufficiency. Bone Marrow Transplant. 1997 Oct;20(8):653-656. Pubmedid: 9383228.
  • Valkov N, Gump J, Sullivan D. Quantitative immunofluorescence and immunoelectron microscopy of the topoisomerase II-alpha associated with nuclear matrices from wild-type and drug resistant Chinese hamster ovary cell lines. J Cell Biochem. 1997 Oct;67(1):112-130. Pubmedid: 9328845.
  • Lock R, Thompson B, Sullivan D, Stribinskiene L. Potentiation of etoposide-induced apoptosis by staurosporine in human tumor cells is associated with events downstream of DNA-protein complex formation. Cancer Chemother Pharmacol. 1997;39(5):399-409. Pubmedid: 9054953.
  • Futscher B, Foley N, Gleason-Guzman M, Meltzer P, Sullivan D, Dalton W. Verapamil suppresses the emergence of P-glycoprotein-mediated multi-drug resistance. Int J Cancer. 1996 May;66(4):520-525. Pubmedid: 8635868.
  • Harker W, Slade D, Parr R, Feldhoff P, Sullivan D, Holguin M. Alterations in the Topoisomerase II-alpha gene, messenger RNA, and subcellular protein distribution as well as reduced expression of the DNA topoisomerase II-beta enzyme in a mitoxantrone-resistant HL-60 human leukemia cell line. Cancer Res. 1995 Apr;55(8):1707-1716. Pubmedid: 7712479.
  • Sullivan D, Feldhoff P, Lock R, Smith N, Pierce W. Characterization of an altered DNA topoisomerase II-alpha from a mitoxantrone resistant mammalian cell line hypersensitive to DNA crosslinking agents. Int J Oncology. 1995;7:1383-1393. Pubmedid: noPMID.
  • Feldhoff P, Mirski S, Cole S, Sullivan D. Altered subcellular distribution of topoisomerase II (alpha) in a drug-resistant human small cell lung cancer cell line. Cancer Res. 1994 Feb;54(3):756-762. Pubmedid: 8306338.
  • Burden D, Sullivan D. Phosphorylation of the (alpha) and (beta) isoforms of DNA topoisomerase II is qualitatively different in interphase and mitosis in Chinese hamster ovary cells. Biochemistry. 1994 Dec;33(49):14651-14655. Pubmedid: 7993892.
  • Blumenrich M, Kellihan J, Joseph U, Lalley K, Sherrill E, Sullivan D, Hamm J, Gentile P, Sheth S, Seeger J, Woodcock T. Long-term intravenous hydroxyurea infusion in patients with advanced cancer. Cancer. 1993 May;71(9):2828-2832. Pubmedid: 7682153.
  • Kroll D, Sullivan D, Gutierrez-Hartmann, Hoeffler J. Modification of DNA topoisomerase II activity via direct interactions with the cyclic adenosine-3',5'-monophosphate response element-binding protein and related transcription factors. Mol Endocrinol. 1993 Mar;7(3):305-318. Pubmedid: 8387155.
  • Burden D, Goldsmith L, Sullivan D. Cell cycle-dependent phosphorylation and activity of Chinese hamster ovary topoisomerase II. Biochem J. 1993 Jul;293(Pt 1):297-304. Pubmedid: 8392338.
  • Sullivan DM, Eskildsen LA, Groom KR, Webb CD, Latham MD, Martin AW, Wellhausen SR, Kroeger PE, Rowe TC. Topoisomerase II activity involved in cleaving DNA into topological domains is altered in a multiple drug-resistant Chinese hamster ovary cell line. Mol Pharmacol. 1993 Feb;43(2):207-216. Pubmedid: 8094226.
  • Stoddard M, Seeger J, Liddell N, Hadley T, Sullivan D, Kupersmith J. J Am Coll Cardiol. 1992;20:62-69. Pubmedid: 1607540.
  • Fields K, Perkins J, Elfenbein G, Goldstein S, Sullivan D, Pertyka J, Trudeau W. Evaluation of prognostic factors for patients with breast cancer undergoing high-dose chemotherapy and autologous stem cell transplant: a single institution experience. In: Dicke K, Keating A, eds. Autologous blood and marrow transplantation, proceedings of the 9th international symposium. Charlottesville, VA: Carden Jennings; 1999;341-352.
  • Fields K, Perkins J, Goldstein S, Elfenbein G, Saez R, Sullivan D, Partyka J, Kronish L. High dose chemotherapy for the treatment of high risk, early stage breast cancer: analysis of risk factors. In: Untech M, Konecny G, Sittek H, Kessler M, et al, eds. Diagnostik and Therapie Des Mammakarzinoms. Verlag, Munchen. W. Zuckeschwerdt; 1998.
  • Fields K, Goldstein S, Clark R, Sullivan D. Breast Cancer. In: Djulbegovic B, Sullivan D, eds. Decision Making in Oncology: Evidence Based Management. New York, NY: Churchill Livingstone Inc.; 1997;253-265.
  • Bhalla K, Gerson S, Grant S, Sullivan D. Pharmacology and molecular mechanism of action or resistance of antineoplastic agents: current status and future potential. In: Hoffman R, Benz E, Shattil S, Furie B, et al, eds. Hematology: basic principles and practice. New York, NY: Chuchhill Livingston; 2000;885-938.